Log In
BCIQ
Print this Print this
 

Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)

  Manage Alerts
Collapse Summary Pipeline Information
 Pipeline Summary for Products Targeting Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)

BCIQ
Print ChartPrint this
1 - Autoimmune 1 - Autoimmune 1 - Renal 1 - Ophthalmic 1 - Inflammation 1 - Endocrine / Metabolic 1 - Dermatology 1 - Cardiovascular 1 - Autoimmune 1 - Cancer 1 - Renal 1 - Neurology 1 - Hematology 1 - Endocrine / Metabolic 1 - Cardiovascular 1 - Cancer 1 - Autoimmune 1 - Renal 1 - Neurology 1 - Autoimmune
Phase of DevelopmentPreclinicalPhase IPhase I/IIPhase IIPhase IIIMarketed
Autoimmune

1

1

-

1

1

1

Cancer

-

1

1

-

-

-

Cardiovascular

-

1

-

1

-

-

Dermatology

-

-

-

1

-

-

Endocrine / Metabolic

-

1

-

1

-

-

Hematology

-

1

-

-

-

-

Inflammation

-

-

-

1

-

-

Neurology

1

1

-

-

-

-

Ophthalmic

-

-

-

1

-

-

Renal

1

1

-

1

-

-




 Products Targeting Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Summary
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

7

$2,918.0M

$1,134.5M

$790.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury Trial today